Unknown

Dataset Information

0

An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants.


ABSTRACT: As long as the coronavirus disease-2019 (COVID-19) pandemic continues, new variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with altered antigenicity will emerge. The development of vaccines that elicit robust, broad, and durable protection against SARS-CoV-2 variants is urgently required. We have developed a vaccine consisting of the attenuated vaccinia virus Dairen-I (DIs) strain platform carrying the SARS-CoV-2  S gene (rDIs-S). rDIs-S induced neutralizing antibody and T-lymphocyte responses in cynomolgus macaques and human angiotensin-converting enzyme 2 (hACE2) transgenic mice, and the mouse model showed broad protection against SARS-CoV-2 isolates ranging from the early-pandemic strain (WK-521) to the recent Omicron BA.1 variant (TY38-873). Using a tandem mass tag (TMT)-based quantitative proteomic analysis of lung homogenates from hACE2 transgenic mice, we found that, among mice subjected to challenge infection with WK-521, vaccination with rDIs-S prevented protein expression related to the severe pathogenic effects of SARS-CoV-2 infection (tissue destruction, inflammation, coagulation, fibrosis, and angiogenesis) and restored protein expression related to immune responses (antigen presentation and cellular response to stress). Furthermore, long-term studies in mice showed that vaccination with rDIs-S maintains S protein-specific antibody titers for at least 6 months after a first vaccination. Thus, rDIs-S appears to provide broad and durable protective immunity against SARS-CoV-2, including current variants such as Omicron BA.1 and possibly future variants.

SUBMITTER: Ishigaki H 

PROVIDER: S-EPMC9716133 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants.

Ishigaki Hirohito H   Yasui Fumihiko F   Nakayama Misako M   Endo Akinori A   Yamamoto Naoki N   Yamaji Kenzaburo K   Nguyen Cong Thanh CT   Kitagawa Yoshinori Y   Sanada Takahiro T   Honda Tomoko T   Munakata Tsubasa T   Higa Masahiko M   Toyama Sakiko S   Kono Risa R   Takagi Asako A   Matsumoto Yusuke Y   Koseki Aya A   Hayashi Kaori K   Shiohara Masanori M   Ishii Koji K   Saeki Yasushi Y   Itoh Yasushi Y   Kohara Michinori M  

Frontiers in microbiology 20221118


As long as the coronavirus disease-2019 (COVID-19) pandemic continues, new variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with altered antigenicity will emerge. The development of vaccines that elicit robust, broad, and durable protection against SARS-CoV-2 variants is urgently required. We have developed a vaccine consisting of the attenuated vaccinia virus Dairen-I (DIs) strain platform carrying the SARS-CoV-2  <i>S</i> gene (rDIs-S). rDIs-S induced neutralizing antib  ...[more]

Similar Datasets

| S-EPMC9353262 | biostudies-literature
| S-EPMC2886958 | biostudies-literature
| S-EPMC404098 | biostudies-literature
| S-EPMC7103406 | biostudies-literature
| S-EPMC3035556 | biostudies-literature
| PRJDB14324 | ENA
| PRJNA739246 | ENA
| PRJNA655789 | ENA
| PRJDB15180 | ENA
| PRJNA799035 | ENA